Remission of Late-Onset Post-Liver Transplantation Non-Hodgkin Lymphoma

1. Rodríguez-Perálvarez M, De la Mata M, Burroughs AK: Liver transplantation: immunosuppression and oncology. Current opinion in organ transplantation 2014, 19(3):253.10.1097/MOT.0000000000000069Search in Google Scholar

2. Gallego-Melcon S, Sanchez de Toledo J, Martinez V, Moraga F, Iglesias J, Ruiz C, Allende E: Non-Hodgkin’s lymphoma after liver transplantation: response to chemotherapy. Med Pediatr Oncol 1996, 27(3):156-159.10.1002/(SICI)1096-911X(199609)27:3<156::AID-MPO4>3.0.CO;2-DOpen DOISearch in Google Scholar

3. Clarke CA, Morton LM, Lynch C, Pfeiffer RM, Hall EC, Gibson TM, Weisenburger DD, Martinez- Maza O, Hussain SK, Yang J et al: Risk of lymphoma subtypes after solid organ transplantation in the United States. Br J Cancer 2013, 109(1):280-288.10.1038/bjc.2013.294Search in Google Scholar

4. Taylor AL, Marcus R, Bradley JA: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Critical reviews in oncology/ hematology 2005, 56(1):155-167.10.1016/j.critrevonc.2005.03.015Search in Google Scholar

5. Huang Q, Yang T, Jin X, Ni X, Qi H, Yan Z: Remission of late-onset post-heart transplantation lymphoproliferative disorder following treatment with rituximab and modified mini-CHOP chemotherapy: A case report. Experimental and therapeutic medicine 2016, 12(1):262-266.10.3892/etm.2016.3310Search in Google Scholar

6. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES: The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011, 117(19):5019-5032.10.1182/blood-2011-01-293050Search in Google Scholar

7. Kinch A, Baecklund E, Backlin C, Ekman T, Molin D, Tufveson G, Fernberg P, Sundstrom C, Pauksens K, Enblad G: A population-based study of 135 lymphomas after solid organ transplantation: The role of Epstein-Barr virus, hepatitis C and diffuse large B-cell lymphoma subtype in clinical presentation and survival. Acta Oncol 2014, 53(5):669-679.10.3109/0284186X.2013.844853Open DOISearch in Google Scholar

8. Ghobrial IM, Habermann TM, Maurer MJ, Geyer SM, Ristow KM, Larson TS, Walker RC, Ansell SM, Macon WR, Gores GG et al: Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005, 23(30):7574-7582.10.1200/JCO.2005.01.0934Search in Google Scholar

9. Luskin MR, Heil DS, Tan KS, Choi S, Stadtmauer EA, Schuster SJ, Porter DL, Vonderheide RH, Bagg A, Heitjan DF et al: The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder. Am J Transplant 2015, 15(10):2665-2673.10.1111/ajt.13324Search in Google Scholar

10. Morscio J, Dierickx D, Ferreiro JF, Herreman A, Van Loo P, Bittoun E, Verhoef G, Matthys P, Cools J, Wlodarska I et al: Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders. Am J Transplant 2013, 13(5):1305-1316.2348947410.1111/ajt.12196Search in Google Scholar

11. van Leeuwen MT, Grulich AE, Webster AC, Mc- Credie MR, Stewart JH, McDonald SP, Amin J, Kaldor JM, Chapman JR, Vajdic CM: Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood 2009, 114(3):630-637.10.1182/blood-2009-02-202507Search in Google Scholar

12. Opelz G, Dohler B: Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004, 4(2):222-230.10.1046/j.1600-6143.2003.00325.xOpen DOISearch in Google Scholar

13. Engels EA, Pfeiffer RM, Fraumeni JF, Jr., Kasiske BL, Israni AK, Snyder JJ, Wolfe RA, Goodrich NP, Bayakly AR, Clarke CA et al: Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011, 306(17):1891-1901.10.1001/jama.2011.1592Search in Google Scholar

14. Quinlan SC, Pfeiffer RM, Morton LM, Engels EA: Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States. Am J Hematol 2011, 86(2):206-209.10.1002/ajh.21911Open DOISearch in Google Scholar

15. Dierickx D, Habermann TM: Post-transplantation lymphoproliferative disorders in adults. New England Journal of Medicine 2018, 378(6):549-562.10.1056/NEJMra1702693Search in Google Scholar

16. Khedmat H, Taheri S: Lymphoproliferative disorders in pediatric liver allograft recipients: a review of 212 cases. Hematology/oncology and stem cell therapy 2012, 5(2):84-90.10.5144/1658-3876.2012.84Search in Google Scholar

17. Ito K, Siegelman ES, Stolpen AH, Mitchell DG: MR imaging of complications after liver transplantation. American Journal of Roentgenology 2000, 175(4):1145-1149.10.2214/ajr.175.4.1751145Search in Google Scholar

18. Geissler EK, Schlitt HJ: Immunosuppression for liver transplantation. Gut 2009, 58(3):452-463.10.1136/gut.2008.163527Open DOISearch in Google Scholar

19. Rodriguez-Peralvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gu rusamy KS: Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev 2017, 3:CD011639.10.1002/14651858.CD011639.pub2Search in Google Scholar

20. Al-Mansour Z, Nelson BP, Evens AM: Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Current hematologic malignancy reports 2013, 8(3):173-183.10.1007/s11899-013-0162-5Search in Google Scholar

21. Cockfield S: Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transplant infectious disease 2001, 3(2):70-78.10.1034/j.1399-3062.2001.003002070.xOpen DOISearch in Google Scholar